ResoTher Pharma is pleased to announce the appointment of Dr. Markus Weissbach, MD., PhD., as Chief Medical Officer as of September 1st 2022. Markus’s primary task will be to guide the further development of RTP-026 into patient studies in acute myocardial infarction and enable the success of our early clinical development program.
“I am thrilled to welcome Markus as a strong addition to our leadership team to support the further development of ResoTher Pharma” stated Lone Veng, CEO of ResoTher Pharma. “Markus has a long and deep experience with clinical strategy, drug development and regulatory success across multiple indications, including cardiovascular disease, and has delivered projects both within the context of large pharma, small biotech and from the CRO side.  I feel confident that Markus will be able to make a significant impact on ResoTher Pharma’s important mission – to validate our novel treatment concept for Myocardial Infarction and make a difference for patients”.
Markus is replacing co-founder Thomas Jonassen as Chief Medical Officer, since Thomas is stepping into a new role as Chairman of the company’s Scientific Advisory Board. Lone Veng added: “The company would like to thank Thomas for his great contributions to the success of our phase I and preclinical programs and welcome him as Chair of our Scientific Advisory Board. I very much look forward to working with the newly expanded leadership team and with both Thomas and Markus in their new roles”.